Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Chronic Heart Failure

Free Subscription Articles published in Eur Heart J Retrieve available abstracts of 221 articles: HTML format Text format

Single Articles

July 2018
1. VAN EMPEL V, Brunner-La Rocca HP
   Helping to understand heart failure with preserved ejection fraction.
   Eur Heart J. 2018 Jul 9. pii: 5050878. doi: 10.1093.
   PubMed     Text format    
   
   
   June 2018
2. GORTER TM, Obokata M, Reddy YNV, Melenovsky V, et al
   Exercise unmasks distinct pathophysiologic features in heart failure with preserved ejection fraction and pulmonary vascular disease.
   Eur Heart J. 2018 Jun 26. pii: 5045545. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
   
3. WEBER T, Chirinos JA
   Pulsatile arterial haemodynamics in heart failure.
   Eur Heart J. 2018 Jun 26. pii: 5045547. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
   
4. PACKER M
   Questioning the obvious: does dyspnoea really matter in heart failure?
   Eur Heart J. 2018 Jun 22. pii: 5043114. doi: 10.1093.
   PubMed     Text format    
   
   
   
5. LAM CSP, Voors AA, de Boer RA, Solomon SD, et al
   Heart failure with preserved ejection fraction: from mechanisms to therapies.
   Eur Heart J. 2018 Jun 13. pii: 5037246. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
   May 2018
6. LUSCHER TF
   Mechanisms and outcomes of heart failure: from HFpEF, HFmrEF, and HFrEF to transplantation.
   Eur Heart J. 2018;39:1749-1753.
   PubMed     Text format    
   
   
   
7. ANGERMANN CE, Frantz S, Maack C
   The Comprehensive Heart Failure Centre in Wurzburg, Germany.
   Eur Heart J. 2018;39:1757-1760.
   PubMed     Text format    
   
   
   
8. SWOBODA PP, Plein S
   Heart failure in Diabetic patients.
   Eur Heart J. 2018;39:1755-1757.
   PubMed     Text format    
   
   
   
9. OBOKATA M, Olson TP, Reddy YNV, Melenovsky V, et al
   Haemodynamics, dyspnoea, and pulmonary reserve in heart failure with preserved ejection fraction.
   Eur Heart J. 2018 May 19. pii: 4999864. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
   March 2018
10. VADUGANATHAN M, Solomon SD
    Expanding the global borders of heart failure: the SHOP and PEOPLE studies.
    Eur Heart J. 2018 Mar 22. pii: 4951580. doi: 10.1093.
    PubMed     Text format    
    
    
    
11. FONSECA C
    A Heart Failure Clinic.
    Eur Heart J. 2018;39:826-828.
    PubMed     Text format    
    
    
    
12. BEGGS S, Gardner R
    Thirty years of heart failure.
    Eur Heart J. 2018;39:824-826.
    PubMed     Text format    
    
    
    February 2018
13. EL HARANE N, Kervadec A, Bellamy V, Pidial L, et al
    Acellular therapeutic approach for heart failure: in vitro production of extracellular vesicles from human cardiovascular progenitors.
    Eur Heart J. 2018 Feb 6. pii: 4840711. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    January 2018
14. LAM CSP, Gamble GD, Ling LH, Sim D, et al
    Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study.
    Eur Heart J. 2018 Jan 29. pii: 4829677. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
15. NELSON MD, Wei J, Bairey Merz CN
    Coronary microvascular dysfunction and heart failure with preserved ejection fraction as female-pattern cardiovascular disease: the chicken or the egg?
    Eur Heart J. 2018 Jan 16. pii: 4811982. doi: 10.1093.
    PubMed     Text format    
    
    
    
16. HEINZMANN D, Seizer P
    Mitochondria in heart failure: EMID-sign.
    Eur Heart J. 2018 Jan 3. pii: 4786075. doi: 10.1093.
    PubMed     Text format    
    
    
    
17. LUND LH, Kober L, Swedberg K, Ruschitzka F, et al
    The year in cardiology 2017: heart failure.
    Eur Heart J. 2018 Jan 2. pii: 4774532. doi: 10.1093.
    PubMed     Text format    
    
    
    
18. LUSCHER TF
    Heart failure subgroups: HFrEF, HFmrEF, and HFpEF with or without mitral regurgitation.
    Eur Heart J. 2018;39:1-4.
    PubMed     Text format    
    
    
    
19. PACKER M
    The Future Treatment of Heart Failure?
    Eur Heart J. 2018;39:5-7.
    PubMed     Text format    
    
    
    December 2017
20. TAQUETI VR, Solomon SD, Shah AM, Desai AS, et al
    Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction.
    Eur Heart J. 2017 Dec 26. pii: 4775060. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
21. ARRIGO M, Vodovar N, Nougue H, Sadoune M, et al
    The heart regulates the endocrine response to heart failure: cardiac contribution to circulating neprilysin.
    Eur Heart J. 2017 Dec 13. pii: 4735305. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
22. WILCOX JE, Mann DL
    Beta-blockers for the treatment of heart failure with a mid-range ejection fraction: deja-vu all over again?
    Eur Heart J. 2017 Dec 11. pii: 4728646. doi: 10.1093.
    PubMed     Text format    
    
    
    November 2017
23. MASIP J, Peacock WF, Price S, Cullen L, et al
    Indications and practical approach to non-invasive ventilation in acute heart failure.
    Eur Heart J. 2017 Nov 26. pii: 4654494. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
24. GRASSI G, Mancia G
    'Keep an eye' on the heart: retinal microcirculation disarray in congestive heart failure.
    Eur Heart J. 2017 Nov 23. pii: 4654727. doi: 10.1093.
    PubMed     Text format    
    
    
    
25. NICHOLLS M
    Finn Waagstein MD PhD: Finn Waagstein reflects on his work and research which saw beta-blockers revolutionise the treatment of heart failure patients. Mark Nicholls reports.
    Eur Heart J. 2017;38:3249-3250.
    PubMed     Text format    
    
    
    
26. ROSANO GMC
    HFA Congress 2017: The Congress of the Heart Failure Association of the ESC: a continuous success story, the result of a long-term vision.
    Eur Heart J. 2017;38:3042-3043.
    PubMed     Text format    
    
    
    
27. TOFIELD A
    Heart Failure Congress sets record: The 2017 ESC Heart Failure Association Congress had a new record number of submissions for original science.
    Eur Heart J. 2017;38:3041.
    PubMed     Text format    
    
    
    October 2017
28. NAGELE MP, Barthelmes J, Ludovici V, Cantatore S, et al
    Retinal microvascular dysfunction in heart failure.
    Eur Heart J. 2017 Oct 21. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
29. CLELAND JGF, Bunting KV, Flather MD, Altman DG, et al
    Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials.
    Eur Heart J. 2017 Oct 10. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
30. LUSCHER TF
    Special issues in heart failure: pulmonary hypertension, deranged potassium levels, and haemodynamic profiles.
    Eur Heart J. 2017;38:2857-2859.
    PubMed     Text format    
    
    
    
31. BLANTON RM
    What can haemodynamic profiles teach us about heart failure in the paediatric population?
    Eur Heart J. 2017;38:2910-2911.
    PubMed     Text format    
    
    
    
32. PITT B, Rossignol P
    Serum potassium in patients with chronic heart failure: once we make a U-turn where should we go?
    Eur Heart J. 2017;38:2897-2899.
    PubMed     Text format    
    
    
    
33. CHEN S, Dykes JC, McElhinney DB, Gajarski RJ, et al
    Haemodynamic profiles of children with end-stage heart failure.
    Eur Heart J. 2017;38:2900-2909.
    PubMed     Text format     Abstract available
    
    
    
34. ALDAHL M, Jensen AC, Davidsen L, Eriksen MA, et al
    Associations of serum potassium levels with mortality in chronic heart failure patients.
    Eur Heart J. 2017;38:2890-2896.
    PubMed     Text format     Abstract available
    
    
    September 2017
35. SCHMIEDER RE, Wagner F, Mayr M, Delles C, et al
    The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study.
    Eur Heart J. 2017 Sep 27. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    August 2017
36. SZUMMER K, Wallentin L, Lindhagen L, Alfredsson J, et al
    Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995-2014.
    Eur Heart J. 2017 Aug 29. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
37. FITCHETT D, Butler J, van de Borne P, Zinman B, et al
    Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME(R) trial.
    Eur Heart J. 2017 Aug 28. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
38. LUSCHER TF
    Update on heart failure: biomarkers, intensive therapy, remote monitoring, and cardiomyocyte renewal.
    Eur Heart J. 2017;38:2315-2317.
    PubMed     Text format    
    
    
    
39. DE BOER RA, Meems LMG, van Veldhuisen DJ
    Vitamin D supplementation in heart failure: case closed?
    Eur Heart J. 2017;38:2287-2289.
    PubMed     Text format    
    
    
    July 2017
40. GOLIASCH G, Bartko PE, Pavo N, Neuhold S, et al
    Refining the prognostic impact of functional mitral regurgitation in chronic heart failure.
    Eur Heart J. 2017 Jul 25. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    June 2017
41. LUSCHER TF
    Risk factors for chronic heart failure: obesity, renal dysfunction, arteriovenous fistulas, and amyloid deposition.
    Eur Heart J. 2017;38:1857-1860.
    PubMed     Text format    
    
    
    
42. ROURA S, Galvez-Monton C, Lupon J, Bayes-Genis A, et al
    Biotherapies and biomarkers for cardiovascular diseases: A 15-year journey at the ICREC (Heart Failure and Cardiac Regeneration) Research Laboratory in Barcelona, Spain.
    Eur Heart J. 2017;38:1784-1786.
    PubMed     Text format    
    
    
    
43. CHATTERJEE NA, Singh JP
    Making sense of remote monitoring studies in heart failure.
    Eur Heart J. 2017 Jun 13. doi: 10.1093.
    PubMed     Text format    
    
    
    
44. SUGIHARA S, Burnett JC Jr
    BLAST-AHF: insights into biased AT1 ligands and heart failure. Beginning of the end or end of the beginning?
    Eur Heart J. 2017 Jun 1. doi: 10.1093.
    PubMed     Text format    
    
    
    May 2017
45. MORGAN JM, Kitt S, Gill J, McComb JM, et al
    Remote management of heart failure using implantable electronic devices.
    Eur Heart J. 2017 May 27. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
46. SCUFFHAM PA, Ball J, Horowitz JD, Wong C, et al
    Standard vs. intensified management of heart failure to reduce healthcare costs: results of a multicentre, randomized controlled trial.
    Eur Heart J. 2017 May 20. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
47. ZITTERMANN A, Ernst JB, Prokop S, Fuchs U, et al
    Effect of vitamin D on all-cause mortality in heart failure (EVITA): a 3-year randomized clinical trial with 4000 IU vitamin D daily.
    Eur Heart J. 2017 May 12. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
48. SCHUPKE S, Mehilli J
    Less myocardial scar but greater propensity for heart failure: another gender paradox in myocardial infarction.
    Eur Heart J. 2017 May 5. doi: 10.1093.
    PubMed     Text format    
    
    
    April 2017
49. PANG PS, Butler J, Collins SP, Cotter G, et al
    Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF).
    Eur Heart J. 2017 Apr 27. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
50. BORLAUG BA, Obokata M
    Is it time to recognize a new phenotype? Heart failure with preserved ejection fraction with pulmonary vascular disease.
    Eur Heart J. 2017 Apr 17. doi: 10.1093.
    PubMed     Text format    
    
    
    
51. LUSCHER TF
    From systemic and pulmonary hypertension to heart failure: novel drugs and devices.
    Eur Heart J. 2017;38:1087-1090.
    PubMed     Text format    
    
    
    
52. CLELAND JGF, Mueller C
    What can we learn from SOCRATES: more questions than answers?
    Eur Heart J. 2017;38:1128-1131.
    PubMed     Text format    
    
    
    
53. MCDIARMID AK, Pellicori P, Cleland JG, Plein S, et al
    Taxonomy of segmental myocardial systolic dysfunction.
    Eur Heart J. 2017;38:942-954.
    PubMed     Text format     Abstract available
    
    
    March 2017
54. PIESKE B, Maggioni AP, Lam CS, Pieske-Kraigher E, et al
    Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study.
    Eur Heart J. 2017 Mar 22. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
55. MCCULLOUGH PA, Rios A, Smith B
    Dialysis fistulas and heart failure.
    Eur Heart J. 2017 Mar 17. doi: 10.1093.
    PubMed     Text format    
    
    
    
56. OUWERKERK W, Voors AA, Anker SD, Cleland JG, et al
    Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study.
    Eur Heart J. 2017 Mar 11. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
57. LUSCHER TF
    Frontiers in heart failure: sodium, longitudinal strain, contractility sensor, fatal arrhythmias, and stroke.
    Eur Heart J. 2017;38:693-696.
    PubMed     Text format    
    
    
    
58. ABDUL-RAHIM AH, Perez AC, MacIsaac RL, Jhund PS, et al
    Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials.
    Eur Heart J. 2017;38:742-750.
    PubMed     Text format     Abstract available
    
    
    
59. BAX JJ, Delgado V, Sogaard P, Singh JP, et al
    Prognostic implications of left ventricular global longitudinal strain in heart failure patients with narrow QRS complex treated with cardiac resynchronization therapy: a subanalysis of the randomized EchoCRT trial.
    Eur Heart J. 2017;38:720-726.
    PubMed     Text format     Abstract available
    
    
    February 2017
60. 
    Corrigendum to: Sacubitril/valsartan and low blood pressure in heart failure with reduced ejection fraction [Eur Heart J 2017; doi:10.1093/eurheartj/ehx014].
    Eur Heart J. 2017 Feb 28. doi: 10.1093.
    PubMed     Text format    
    
    
    
61. MULLENS W, Verbrugge FH, Nijst P, Tang WH, et al
    Renal sodium avidity in heart failure: from pathophysiology to treatment strategies.
    Eur Heart J. 2017 Feb 23. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
62. MATHUR A, Fernandez-Aviles F, Dimmeler S, Hauskeller C, et al
    The consensus of the Task Force of the European Society of Cardiology concerning the clinical investigation of the use of autologous adult stem cells for the treatment of acute myocardial infarction and heart failure: update 2016.
    Eur Heart J. 2017 Feb 15. doi: 10.1093.
    PubMed     Text format    
    
    
    
63. BAYES-GENIS A, Voors AA, Zannad F, Januzzi JL, et al
    Transitioning from usual care to biomarker-based personalized and precision medicine in heart failure: call for action.
    Eur Heart J. 2017 Feb 15. doi: 10.1093.
    PubMed     Text format    
    
    
    
64. BOHM M, Young R, Jhund PS, Solomon SD, et al
    Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF.
    Eur Heart J. 2017 Feb 1. doi: 10.1093.
    PubMed     Text format    
    
    
    
65. SINGH A, Laribi S, Teerlink JR, Mebazaa A, et al
    Agents with vasodilator properties in acute heart failure.
    Eur Heart J. 2017;38:317-325.
    PubMed     Text format    
    
    
    
66. LUSCHER TF
    An update on heart failure: from experimental findings to clinical trials.
    Eur Heart J. 2017;38:305-307.
    PubMed     Text format    
    
    
    
67. TOFIELD A
    Teenage weight and risk for adult heart failure.
    Eur Heart J. 2017;38:311-312.
    PubMed     Text format    
    
    
    
68. TOFIELD A
    End of the road for aliskiren in heart failure.
    Eur Heart J. 2017;38:312-313.
    PubMed     Text format    
    
    
    
69. 
    Professor Jay Cohn a pioneer in heart failure.
    Eur Heart J. 2017;38:308-309.
    PubMed     Text format    
    
    
    
70. HARPER AR, Cowie MR
    Remote monitoring for heart failure: the story moves on.
    Eur Heart J. 2017;38:310-311.
    PubMed     Text format    
    
    
    January 2017
71. BRUNO RM, Taddei S
    Sacubril/valsartan and low blood pressure in heart failure with reduced ejection fraction.
    Eur Heart J. 2017 Jan 30. doi: 10.1093.
    PubMed     Text format    
    
    
    
72. HORCKMANS M, Ring L, Duchene J, Santovito D, et al
    Neutrophils orchestrate post-myocardial infarction healing by polarizing macrophages towards a reparative phenotype.
    Eur Heart J. 2017;38:187-197.
    PubMed     Text format    
    
    
    
73. LANDIN AM, Hare JM
    The quest for a successful cell-based therapeutic approach for heart failure.
    Eur Heart J. 2017 Jan 10. pii: ehw626. doi: 10.1093.
    PubMed     Text format    
    
    
    
74. BAVENDIEK U, Aguirre Davila L, Koch A, Bauersachs J, et al
    Assumption versus evidence: the case of digoxin in atrial fibrillation and heart failure.
    Eur Heart J. 2017 Jan 8. pii: ehw577. doi: 10.1093.
    PubMed     Text format    
    
    
    
75. CHATTERJEE NA, Borgquist R, Chang Y, Lewey J, et al
    Increasing sex differences in the use of cardiac resynchronization therapy with or without implantable cardioverter-defibrillator.
    Eur Heart J. 2017 Jan 8. pii: ehw598. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
76. MAGGIONI AP, Ruschitzka F
    The year in cardiology 2016: heart failure.
    Eur Heart J. 2017 Jan 2. pii: ehw638. doi: 10.1093.
    PubMed     Text format    
    
    
    December 2016
77. MAISEL AS, Di Somma S
    Do we need another heart failure biomarker: focus on soluble suppression of tumorigenicity 2 (sST2).
    Eur Heart J. 2016 Dec 27. pii: ehw462. doi: 10.1093.
    PubMed     Text format    
    
    
    
78. NAKAMURA T, Masumoto A, Tahara N, Kuroda Y, et al
    Acute heart failure caused by mechanical valve leaflet dislodgment at the mitral position.
    Eur Heart J. 2016 Dec 23. pii: ehw521. doi: 10.1093.
    PubMed     Text format    
    
    
    
79. BARTUNEK J, Terzic A, Davison BA, Filippatos GS, et al
    Cardiopoietic cell therapy for advanced ischemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial.
    Eur Heart J. 2016 Dec 23. pii: ehw543. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
    
80. HOEPER MM, Lam CS, Vachiery JL, Bauersachs J, et al
    Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further researchdagger.
    Eur Heart J. 2016 Dec 23. pii: ehw597. doi: 10.1093.
    PubMed     Text format    
    
    
    
81. MINOIA C, Paolillo S
    Two weeks at Harvard, for two European heart failure trainees.
    Eur Heart J. 2016;37:3553-3554.
    PubMed     Text format    
    
    
    
82. PAOLILLO S
    The ESC Heart Failure Association postgraduate course in heart failure.
    Eur Heart J. 2016;37:3551-3552.
    PubMed     Text format    
    
    
    November 2016
83. AMMIRATI E, Burns JC, Moreo A, Daniels LB, et al
    Extreme giant aneurysms of three coronary arteries causing heart failure as late sequelae of Kawasaki disease.
    Eur Heart J. 2016.
    PubMed     Text format    
    
    
    
84. 
    What the Heart Failure Congress means to the Heart Failure Association.
    Eur Heart J. 2016;37:3124-3126.
    PubMed     Text format    
    
    
    
85. 
    First European advice launched for acute heart failure.
    Eur Heart J. 2016;37:3123-3124.
    PubMed     Text format    
    
    
    
86. 
    What's new in the European Society of Cardiology 2016 Guidelines for the diagnosis and treatment of acute and chronic heart failure?
    Eur Heart J. 2016;37:3121-3122.
    PubMed     Text format    
    
    
    October 2016
87. CREA F, Bairey Merz CN, Beltrame JF, Kaski JC, et al
    The parallel tales of microvascular angina and heart failure with preserved ejection fraction: a paradigm shift.
    Eur Heart J. 2016.
    PubMed     Text format    
    
    
    
88. DOCHERTY KF, Campbell RT, Jhund PS, Petrie MC, et al
    How robust are clinical trials in heart failure?
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available
    
    
    September 2016
89. JORGE C, Hiltrop N, Desmet W
    Heart failure with preserved ejection fraction: blame the veins....
    Eur Heart J. 2016.
    PubMed     Text format    
    
    
    
90. MOHSENI H, Kiran A, Khorshidi R, Rahimi K, et al
    Influenza vaccination and risk of hospitalization in patients with heart failure: a self-controlled case series study.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available
    
    
    
91. JHUND PS
    Obesity and heart failure: when 'epidemics' collide.
    Eur Heart J. 2016 Sep 22. doi: 10.1093.
    PubMed     Text format    
    
    
    
92. FRADLEY MG
    The evolving field of cardio-oncology: beyond anthracyclines and heart failure.
    Eur Heart J. 2016;37:2740-2742.
    PubMed     Text format    
    
    
    
93. ZHABYEYEV P, Oudit GY
    Unravelling the molecular basis for cardiac iron metabolism and deficiency in heart failure.
    Eur Heart J. 2016.
    PubMed     Text format    
    
    
    
94. KOYAMA M, Yano T, Kikuchi K, Nagahara D, et al
    Lethal heart failure with anti-mitochondrial antibody: an arrhythmogenic right ventricular cardiomyopathy mimetic.
    Eur Heart J. 2016.
    PubMed     Text format    
    
    
    
95. 
    The Acute Heart Failure Academy.
    Eur Heart J. 2016;37:2568-9.
    PubMed     Text format    
    
    
    
96. LUSCHER TF
    From heart failure to transplantation: genes, miRNAs, and biomarkers.
    Eur Heart J. 2016;37:2561-3.
    PubMed     Text format    
    
    
    August 2016
97. HADDAD S, Wang Y, Galy B, Korf-Klingebiel M, et al
    Iron-regulatory proteins secure iron availability in cardiomyocytes to prevent heart failure.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available
    
    
    
98. LAM CS, Teng TK, Tay WT, Anand I, et al
    Regional and ethnic differences among patients with heart failure in Asia: the Asian sudden cardiac death in heart failure registry.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available
    
    
    July 2016
99. ZANNAD F, Ferreira JP
    Globalization of heart failure trials: no turning back on this paradigm.
    Eur Heart J. 2016.
    PubMed     Text format    
    
    
    
100. LUSCHER TF
     Breaking news in heart failure: ESC Guidelines 2016, non-steroidal mineralocorticoid receptor antagonist, and alternate site CRT pacing.
     Eur Heart J. 2016;37:2085-7.
     PubMed     Text format    
     
     
     
101. HINDRICKS G, Varma N
     Remote monitoring and heart failure: monitoring parameters, technology, and workflow.
     Eur Heart J. 2016.
     PubMed     Text format    
     
     
     June 2016
102. KRISTENSEN SL, Martinez F, Jhund PS, Arango JL, et al
     Geographic variations in the PARADIGM-HF heart failure trial.
     Eur Heart J. 2016.
     PubMed     Text format     Abstract available
     
     
     
103. VON ROEDER M, Rommel KP, Blazek S, Daehnert I, et al
     Pressure-volume-loop-guided closure of an iatrogenic atrial septal defect for right heart failure following MitraClip-implantation.
     Eur Heart J. 2016.
     PubMed     Text format    
     
     
     
104. EPSTEIN M, Pitt BC
     A propitious time for initiating clinical trials in patients with heart failure with reduced ejection fraction and an estimated glomerular filtration rate <30 mL/min with an mineralocorticoid receptor antagonist and a K+ binder: 'the forbidden frui
     Eur Heart J. 2016.
     PubMed     Text format    
     
     
     
105. BORLAUG BA, Kane GC, Melenovsky V, Olson TP, et al
     Abnormal right ventricular-pulmonary artery coupling with exercise in heart failure with preserved ejection fraction.
     Eur Heart J. 2016.
     PubMed     Text format     Abstract available
     
     
     
106. ROSENGREN A, Aberg M, Robertson J, Waern M, et al
     Body weight in adolescence and long-term risk of early heart failure in adulthood among men in Sweden.
     Eur Heart J. 2016.
     PubMed     Text format     Abstract available
     
     
     
107. LUSCHER TF
     Frontiers in heart failure: assessement, risk factors, and novel genetic and cell-based therapies.
     Eur Heart J. 2016;37:1629-32.
     PubMed     Text format    
     
     
     
108. FERREIRA JP, Girerd N, Alshalash S, Konstam MA, et al
     Antithrombotic therapy in heart failure patients with and without atrial fibrillation: update and future challenges.
     Eur Heart J. 2016.
     PubMed     Text format     Abstract available
     
     
     May 2016
109. PONIKOWSKI P, Voors AA, Anker SD, Bueno H, et al
     2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contributio
     Eur Heart J. 2016.
     PubMed     Text format    
     
     
     
110. ANTMAN EM, Bax J, Chazal RA, Creager MA, et al
     Updated Clinical Practice Guidelines on Heart Failure: An International Alignment.
     Eur Heart J. 2016.
     PubMed     Text format    
     
     
     
111. LUSCHER TF
     Frontiers in congenital heart disease: pulmonary hypertension, heart failure, and arrhythmias.
     Eur Heart J. 2016;37:1407-9.
     PubMed     Text format    
     
     
     April 2016
112. NAEGELE M, Hernandez AF, Ruschitzka F
     Finerenone in heart failure: walking a fine line.
     Eur Heart J. 2016.
     PubMed     Text format    
     
     
     
113. FILIPPATOS G, Anker SD, Bohm M, Gheorghiade M, et al
     A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease.
     Eur Heart J. 2016.
     PubMed     Text format     Abstract available
     
     
     
114. ARAS MA, Teerlink JR
     Lung ultrasound: a 'B-line' to the prediction of decompensated heart failure.
     Eur Heart J. 2016;37:1252-4.
     PubMed     Text format    
     
     
     
115. LUSCHER TF
     Imaging as a basis of clinical decision-making in congenital and coronary disease and heart failure.
     Eur Heart J. 2016;37:1171-3.
     PubMed     Text format    
     
     
     
116. SMISETH OA, Torp H, Opdahl A, Haugaa KH, et al
     Myocardial strain imaging: how useful is it in clinical decision making?
     Eur Heart J. 2016;37:1196-207.
     PubMed     Text format     Abstract available
     
     
     
117. PATIL NP, Weymann A, Popov AF, Simon AR, et al
     Chest X-ray in cardiac illness: a tale of four decades.
     Eur Heart J. 2016;37:1243.
     PubMed     Text format    
     
     
     
118. DESAI AS, Jhund PS
     After TOPCAT: What to do now in Heart Failure with Preserved Ejection Fraction.
     Eur Heart J. 2016.
     PubMed     Text format     Abstract available
     
     
     
119. BAHLS M, Felix SB
     Cachexia and right ventricular dysfunction in chronic heart failure: what is the chicken and what the egg?
     Eur Heart J. 2016.
     PubMed     Text format    
     
     
     
120. SCHWARZL M, Ojeda F, Zeller T, Seiffert M, et al
     Risk factors for heart failure are associated with alterations of the LV end-diastolic pressure-volume relationship in non-heart failure individuals: data from a large-scale, population-based cohort.
     Eur Heart J. 2016.
     PubMed     Text format     Abstract available
     
     
     
121. MADONNA R, Van Laake LW, Davidson SM, Engel FB, et al
     Position Paper of the European Society of Cardiology Working Group Cellular Biology of the Heart: cell-based therapies for myocardial repair and regeneration in ischemic heart disease and heart failure.
     Eur Heart J. 2016.
     PubMed     Text format     Abstract available
     
     
     
122. SCHMIDT M, Lamberts M, Olsen AM, Fosboll E, et al
     Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology.
     Eur Heart J. 2016;37:1015-23.
     PubMed     Text format    
     
     
     March 2016
123. LUSCHER TF
     Update on hypertension: target blood pressure, comorbidities, and outcome.
     Eur Heart J. 2016;37:921-3.
     PubMed     Text format    
     
     
     
124. BOHM M, Drexler H, Oswald H, Rybak K, et al
     Fluid status telemedicine alerts for heart failure: a randomized controlled trial.
     Eur Heart J. 2016.
     PubMed     Text format     Abstract available
     
     
     
125. AUER J, Wallner M, Windpessl M, Schmidt WM, et al
     Acute decompensated heart failure associated with a heteroplasmic 3243A>G mitochondrial DNA point mutation.
     Eur Heart J. 2016.
     PubMed     Text format    
     
     
     
126. BRAUNWALD E
     Academic-industrial collaboration in the development of the first angiotensin receptor blocker: neprilysin inhibitor in the treatment of heart failure.
     Eur Heart J. 2016;37:745-6.
     PubMed     Text format    
     
     
     February 2016
127. HULOT JS, Ishikawa K, Hajjar RJ
     Gene therapy for the treatment of heart failure: promise postponed.
     Eur Heart J. 2016.
     PubMed     Text format     Abstract available
     
     
     
128. SWEDBERG K, Ryden L
     Treatment of diabetes and heart failure: joint forces.
     Eur Heart J. 2016.
     PubMed     Text format    
     
     
     
129. LOCH A, Geh DJ, Veriah RS
     Cardiac magnetic resonance imaging: a tool to diagnose parasitic infection?
     Eur Heart J. 2016;37:702.
     PubMed     Text format    
     
     
     
130. VALENTOVA M, von Haehling S, Bauditz J, Doehner W, et al
     Intestinal congestion and right ventricular dysfunction: a link with appetite loss, inflammation, and cachexia in chronic heart failure.
     Eur Heart J. 2016.
     PubMed     Text format     Abstract available
     
     
     
131. SINGH A, Laribi S, Teerlink JR, Mebazaa A, et al
     Agents with vasodilator properties in acute heart failure.
     Eur Heart J. 2016.
     PubMed     Text format     Abstract available
     
     
     
132. LUSCHER TF
     Heart failure and left ventricular remodelling in HFrEF and HFpEF.
     Eur Heart J. 2016;37:423-4.
     PubMed     Text format    
     
     
     
133. STROMBERG A, Wodlin P
     CardioPulse; Pocket-sized ultrasound for nurses in heart failure?
     Eur Heart J. 2016;37:434-5.
     PubMed     Text format    
     
     
     
134. TCHAMBAZ L
     CardioPulse: The second Postgraduate Course in Heart Failure: 2016-2017.
     Eur Heart J. 2016;37:430-1.
     PubMed     Text format    
     
     
     
135. BORLAUG BA
     Defining HFpEF: where do we draw the line?
     Eur Heart J. 2016;37:463-5.
     PubMed     Text format    
     
     
     
136. DWECK M, Chin C
     CardioPulse: Settling scores with a failing heart.
     Eur Heart J. 2016;37:433-4.
     PubMed     Text format    
     
     
     
137. WESTENBRINK BD, van Laake LW, Brugts JJ
     CardioPulse: The Postgraduate Course in Heart Failure.
     Eur Heart J. 2016;37:428-9.
     PubMed     Text format    
     
     
     
138. DIMARCO A, Mansoubi H, Tanner M
     An unusual cause of left ventricular hypertrophy.
     Eur Heart J. 2016;37:497.
     PubMed     Text format    
     
     
     
139. LECLERCQ C, Sadoul N, Mont L, Defaye P, et al
     Comparison of right ventricular septal pacing and right ventricular apical pacing in patients receiving cardiac resynchronization therapy defibrillators: the SEPTAL CRT Study.
     Eur Heart J. 2016;37:473-83.
     PubMed     Text format     Abstract available
     
     
     
140. STONE GW, Chung ES, Stancak B, Svendsen JH, et al
     Peri-infarct zone pacing to prevent adverse left ventricular remodelling in patients with large myocardial infarction.
     Eur Heart J. 2016;37:484-93.
     PubMed     Text format     Abstract available
     
     
     January 2016
141. FITCHETT D, Zinman B, Wanner C, Lachin JM, et al
     Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial.
     Eur Heart J. 2016.
     PubMed     Text format     Abstract available
     
     
     
142. PLATZ E, Lewis EF, Uno H, Peck J, et al
     Detection and prognostic value of pulmonary congestion by lung ultrasound in ambulatory heart failure patientsdagger.
     Eur Heart J. 2016.
     PubMed     Text format     Abstract available
     
     
     
143. WANG K, Long B, Liu F, Wang JX, et al
     A circular RNA protects the heart from pathological hypertrophy and heart failure by targeting miR-223.
     Eur Heart J. 2016.
     PubMed     Text format     Abstract available
     
     
     
144. RABER L, Piccolo R
     CardioPulse: Different bleeding scores and which one should we use?
     Eur Heart J. 2016;37:327-31.
     PubMed     Text format    
     
     
     
145. BUDTS W, Roos-Hesselink J, Radle-Hurst T, Eicken A, et al
     Treatment of heart failure in adult congenital heart disease: a position paper of the Working Group of Grown-Up Congenital Heart Disease and the Heart Failure Association of the European Society of Cardiology.
     Eur Heart J. 2016.
     PubMed     Text format    
     
     
     
146. NICHOLLS M
     CardioPulse: Cyclosporine to reduce myocardial infarction injury?
     Eur Heart J. 2016;37:210-1.
     PubMed     Text format    
     
     
     
147. KOMAJDA M, Ruschitzka F
     The year in cardiology 2015: heart failure.
     Eur Heart J. 2016.
     PubMed     Text format    
     
     
     December 2015
148. IUNG B, Doco-Lecompte T, Chocron S, Strady C, et al
     Cardiac surgery during the acute phase of infective endocarditis: discrepancies between European Society of Cardiology guidelines and practices.
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     
149. HIGASHI H, Inaba S, Izutani H, Sumimoto T, et al
     An unusual cause of life-threatening right-sided heart failure: undifferentiated pleomorphic sarcoma in the right ventricular outflow tract.
     Eur Heart J. 2015.
     PubMed     Text format    
     
     
     November 2015
150. PULS M, Lubos E, Boekstegers P, von Bardeleben RS, et al
     One-year outcomes and predictors of mortality after MitraClip therapy in contemporary clinical practice: results from the German transcatheter mitral valve interventions registry.
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     
151. OLDENBURG O, Wellmann B, Buchholz A, Bitter T, et al
     Nocturnal hypoxaemia is associated with increased mortality in stable heart failure patients.
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     
152. LUSCHER TF
     Infections, infarction, and heart failure: prevention and management.
     Eur Heart J. 2015;36:3033-5.
     PubMed     Text format    
     
     
     
153. MCMURRAY JJ
     Improving outcomes in heart failure: a personal perspectivedagger.
     Eur Heart J. 2015.
     PubMed     Text format    
     
     
     
154. SKOURI H, Dickstein K
     Heart failure in the Middle East An Emerging Challenge in a Diverse Environment.
     Eur Heart J. 2015;36:2970-2.
     PubMed     Text format    
     
     
     
155. VAN VELDHUISEN DJ, Ruilope LM, Maisel AS, Damman K, et al
     Biomarkers of renal injury and function: diagnostic, prognostic and therapeutic implications in heart failure.
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     
156. WANG N, Hung CL, Shin SH, Claggett B, et al
     Regional cardiac dysfunction and outcome in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction.
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     October 2015
157. ROSENKRANZ S, Gibbs JS, Wachter R, De Marco T, et al
     Left ventricular heart failure and pulmonary hypertensiondagger.
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     
158. KATZ AM, Rolett EL
     Heart failure: when form fails to follow function.
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     September 2015
159. KOTECHA D, Piccini JP
     Atrial fibrillation in heart failure: what should we do?
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     
160. KASTRUP J
     Revival of cytokine therapy in heart failure?
     Eur Heart J. 2015.
     PubMed     Text format    
     
     
     
161. CIKES M, Solomon SD
     Beyond ejection fraction: an integrative approach for assessment of cardiac structure and function in heart failure.
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     
162. FRANCIS GS, Thenappan T
     Beta-blockers in heart failure: do we finally have the last word?
     Eur Heart J. 2015.
     PubMed     Text format    
     
     
     
163. SOLOMON SD, Claggett B, Lewis EF, Desai A, et al
     Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction.
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     
164. NICHOLLS M
     Research providing new insights into myocardial infarction injury.
     Eur Heart J. 2015;36:2345-6.
     PubMed     Text format    
     
     
     
165. LUSCHER TF
     Risk factors for and management of heart failure.
     Eur Heart J. 2015;36:2267-9.
     PubMed     Text format    
     
     
     August 2015
166. GORCSAN J 3RD, Sogaard P, Bax JJ, Singh JP, et al
     Association of persistent or worsened echocardiographic dyssynchrony with unfavourable clinical outcomes in heart failure patients with narrow QRS width: a subgroup analysis of the EchoCRT trial.
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     
167. MALASA M, Werner N, Nickenig G, Hammerstingl C, et al
     Transcatheter tricuspid valve repair in a patient with isolated functional tricuspid valve regurgitation.
     Eur Heart J. 2015.
     PubMed     Text format    
     
     
     
168. GORCSAN J 3RD, Schwartzman D
     Ventricular arrhythmias after cardiac resynchronization therapy: does reverse remodelling reverse risk?
     Eur Heart J. 2015.
     PubMed     Text format    
     
     
     
169. LUSCHER TF
     Prevention of non-communicable diseases and special causes of heart failure.
     Eur Heart J. 2015;36:2019-2022.
     PubMed     Text format    
     
     
     
170. CHATTERJEE NA, Roka A, Lubitz SA, Gold MR, et al
     Reduced appropriate implantable cardioverter-defibrillator therapy after cardiac resynchronization therapy-induced left ventricular function recovery: a meta-analysis and systematic review.
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     
171. LUSCHER TF
     Novel aspects of heart failure: from combined neurohormal blockade to embryonic stem cells.
     Eur Heart J. 2015;36:1937-9.
     PubMed     Text format    
     
     
     
172. TAYLOR J
     Depression associated with five-fold increased mortality risk in heart failure patients.
     Eur Heart J. 2015;36:1946.
     PubMed     Text format    
     
     
     
173. TAYLOR J
     Cognitive impairment predicts worse outcome in heart failure.
     Eur Heart J. 2015;36:1945.
     PubMed     Text format    
     
     
     
174. TOFIELD A
     Digoxin mortality in heart failure and atrial fibrillation.
     Eur Heart J. 2015;36:1944-5.
     PubMed     Text format    
     
     
     
175. PERRONE-FILARDI P, Paolillo S, Costanzo P, Savarese G, et al
     The role of metabolic syndrome in heart failure.
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     July 2015
176. GONZALEZ-LOPEZ E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, et al
     Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     
177. CASTANO A, Bokhari S, Maurer MS
     Unveiling wild-type transthyretin cardiac amyloidosis as a significant and potentially modifiable cause of heart failure with preserved ejection fraction.
     Eur Heart J. 2015.
     PubMed     Text format    
     
     
     
178. CORRADO D, Wichter T, Link MS, Hauer R, et al
     Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement.
     Eur Heart J. 2015.
     PubMed     Text format    
     
     
     
179. DICKSTEIN K
     Is substantial renal dysfunction in patients with heart failure no longer a contraindication for RAS inhibition? The power of a large, high-quality registry to illuminate major clinical issues.
     Eur Heart J. 2015.
     PubMed     Text format    
     
     
     
180. HOENDERMIS ES, Liu LC, Hummel YM, van der Meer P, et al
     Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial.
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     
181. BORLAUG BA
     Taking aim at pulmonary hypertension in heart failure with preserved ejection fraction.
     Eur Heart J. 2015.
     PubMed     Text format    
     
     
     
182. STONE GW, Adams DH, Abraham WT, Kappetein AP, et al
     Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 2: endpoint definitions: A consensus document from the Mitral Valve Academic Research Consortium.
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     
183. GUO J, Mihic A, Wu J, Zhang Y, et al
     Canopy 2 attenuates the transition from compensatory hypertrophy to dilated heart failure in hypertrophic cardiomyopathy.
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     
184. MUNZEL T, Gori T, Keaney JF Jr, Maack C, et al
     Pathophysiological role of oxidative stress in systolic and diastolic heart failure and its therapeutic implications.
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     June 2015
185. FADINI GP, Avogaro A, Degli Esposti L, Russo P, et al
     Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database.
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     
186. TOFIELD A
     Blood sugar levels in heart failure patients predict risk of early death, hospitalizations, and diabetes.
     Eur Heart J. 2015;36:1498-9.
     PubMed     Text format    
     
     
     
187. GIRERD N, Collier T, Pocock S, Krum H, et al
     Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial.
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     
188. FELKER GM
     Augmenting outcomes in patients with advanced heart failure.
     Eur Heart J. 2015.
     PubMed     Text format    
     
     
     
189. YSSAP J, Lebreton G, Hoen B, Larifla L, et al
     Infected left ventricular thrombus revealing an unrecognized coronary dissection after blunt chest trauma, treated with emergency heart transplantation.
     Eur Heart J. 2015.
     PubMed     Text format    
     
     
     
190. PARKER JD
     Therapeutic developments in the therapy of heart failure: lessons to be learned.
     Eur Heart J. 2015.
     PubMed     Text format    
     
     
     
191. ANKER SD, Coats AJ, Cristian G, Dragomir D, et al
     A prospective comparison of alginate-hydrogel with standard medical therapy to determine impact on functional capacity and clinical outcomes in patients with advanced heart failure (AUGMENT-HF trial).
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     
192. FANKHAUSER CD, Nietlispach F, Emmert MY, Maisano F, et al
     Antegrade valve embolization after transcatheter treatment for pure aortic regurgitation.
     Eur Heart J. 2015.
     PubMed     Text format    
     
     
     
193. LUSCHER TF
     Heart failure and comorbidities: renal failure, diabetes, atrial fibrillation, and inflammation.
     Eur Heart J. 2015;36:1415-7.
     PubMed     Text format    
     
     
     
194. EDNER M, Benson L, Dahlstrom U, Lund LH, et al
     Association between renin-angiotensin system antagonist use and mortality in heart failure with severe renal insufficiency: a prospective propensity score-matched cohort study.
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     
195. CHUNG ES, Miller L, Patel AN, Anderson RD, et al
     Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized Phase II trial.
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     
196. AMSTEIN R, Luscher TF, Maisano F, Ruschitzka FT, et al
     The new postgraduate course in heart failure (PCHF): update on 1st PCHF and announcement of the 2nd PCHF. A project of the European Society of Cardiology Heart Failure Association, the ESC European Heart Academy, the Zurich Heart House and the Univers
     Eur Heart J. 2015;36:1354-5.
     PubMed     Text format    
     
     
     May 2015
197. DESAI AS, McMurray JJ, Packer M, Swedberg K, et al
     Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients.
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     
198. MEBAZAA A, Yilmaz MB, Levy P, Ponikowski P, et al
     Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Em
     Eur Heart J. 2015.
     PubMed     Text format    
     
     
     
199. MENASCHE P, Vanneaux V, Hagege A, Bel A, et al
     Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: first clinical case report.
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     
200. FLORAS JS, Ponikowski P
     The sympathetic/parasympathetic imbalance in heart failure with reduced ejection fraction.
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     
201. SLIWA K, Johnson MR, Zilla P, Roos-Hesselink JW, et al
     Management of valvular disease in pregnancy: a global perspective.
     Eur Heart J. 2015;36:1078-89.
     PubMed     Text format     Abstract available
     
     
     
202. HILFIKER-KLEINER D, Haghikia A, Nonhoff J, Bauersachs J, et al
     Peripartum cardiomyopathy: current management and future perspectives.
     Eur Heart J. 2015;36:1090-7.
     PubMed     Text format     Abstract available
     
     
     
203. BUCKLEY U, Shivkumar K
     Implantable cardioverter defibrillators: even better than we thought?
     Eur Heart J. 2015.
     PubMed     Text format    
     
     
     April 2015
204. RAPHAEL CE, Finegold JA, Barron AJ, Whinnett ZI, et al
     The effect of duration of follow-up and presence of competing risk on lifespan-gain from implantable cardioverter defibrillator therapy: who benefits the most?
     Eur Heart J. 2015.
     PubMed     Text format     Abstract available
     
     
     
205. SOLOMON S, Goncalves A
     CardioPulse: drinking moderate amounts of alcohol is linked to reduced risk of heart failure.
     Eur Heart J. 2015;36:890-1.
     PubMed     Text format    
     
     
     
206. CONEN D
     Alcohol consumption and incident cardiovascular disease: not just one unifying hypothesis.
     Eur Heart J. 2015;36:897-8.
     PubMed     Text format    
     
     
     
207. 
     Stem cells for heart failure: the experience of writing a Cochrane systematic review.
     Eur Heart J. 2015;36:834-6.
     PubMed     Text format    
     
     
     
208. HILFIKER-KLEINER D, Westhoff-Bleck M, Gunter HH, von Kaisenberg CS, et al
     A management algorithm for acute heart failure in pregnancy. The Hannover experience.
     Eur Heart J. 2015;36:769-70.
     PubMed     Text format    
     
     
     March 2015
209. AMINZADEH MA, Tseliou E, Sun B, Cheng K, et al
     Therapeutic efficacy of cardiosphere-derived cells in a transgenic mouse model of non-ischaemic dilated cardiomyopathy.
     Eur Heart J. 2015;36:751-62.
     PubMed     Text format     Abstract available
     
     
     
210. SAVVATIS K, Schultheiss HP, Tschope C
     Endomyocardial biopsy and ultrastructural changes in dilated cardiomyopathy: taking a 'deeper' look into patients' prognosis.
     Eur Heart J. 2015;36:708-10.
     PubMed     Text format    
     
     
     
211. NABETA T, Itatani K, Miyaji K, Ako J, et al
     Vortex flow energy loss reflects therapeutic effect in dilated cardiomyopathy.
     Eur Heart J. 2015;36:637.
     PubMed     Text format    
     
     
     February 2015
212. CALIFF RM
     LCZ696: too good to be true?
     Eur Heart J. 2015;36:410-2.
     PubMed     Text format    
     
     
     
213. LUBITZ SA, Singh JP
     Biventricular pacing: more is better!
     Eur Heart J. 2015;36:407-9.
     PubMed     Text format    
     
     
     January 2015
214. BANYPERSAD SM, Fontana M, Maestrini V, Sado DM, et al
     T1 mapping and survival in systemic light-chain amyloidosis.
     Eur Heart J. 2015;36:244-51.
     PubMed     Text format     Abstract available
     
     
     September 2014
215. MIZIA-STEC K, Wybraniec MT, Bochenek T, Gierlaszynska K, et al
     Fulminant variant of Loeffler disease mimicking arrhythmogenic right ventricular cardiomyopathy in the course of enterobiasis.
     Eur Heart J. 2014.
     PubMed     Text format    
     
     
     
216. CLAEYS MJ
     High-sensitivity troponin: does it predict the shape of the iceberg underneath the surface?
     Eur Heart J. 2014;35:2273-5.
     PubMed     Text format    
     
     
     
217. KAYE GC, Linker NJ, Marwick TH, Pollock L, et al
     Effect of right ventricular pacing lead site on left ventricular function in patients with high-grade atrioventricular block: results of the Protect-Pace study.
     Eur Heart J. 2014.
     PubMed     Text format     Abstract available
     
     
     August 2014
218. FERRARI R, Rizzo P
     The Notch pathway: a novel target for myocardial remodelling therapy?
     Eur Heart J. 2014;35:2140-5.
     PubMed     Text format     Abstract available
     
     
     
219. NENSA F, Poeppel TD, Krings P, Schlosser T, et al
     Multiparametric assessment of myocarditis using simultaneous positron emission tomography/magnetic resonance imaging.
     Eur Heart J. 2014;35:2173.
     PubMed     Text format    
     
     
     
220. RUWALD AC, Kutyifa V, Ruwald MH, Solomon S, et al
     The association between biventricular pacing and cardiac resynchronization therapy-defibrillator efficacy when compared with implantable cardioverter defibrillator on outcomes and reverse remodelling.
     Eur Heart J. 2014.
     PubMed     Text format     Abstract available
     
     
     May 2014
221. CHIN CW, Shah AS, McAllister DA, Joanna Cowell S, et al
     High-sensitivity troponin I concentrations are a marker of an advanced hypertrophic response and adverse outcomes in patients with aortic stenosis.
     Eur Heart J. 2014.
     PubMed     Text format     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Chronic Heart Failure is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: